OvaGene Inks Deal for miRNA Biomarkers for Cancer Drug Response | GenomeWeb

OvaGene said this week that it has signed a licensing and collaboration agreement with the Moffitt Cancer Center to develop microRNAs as biomarkers for cancer drug response.

OvaGene said it now has the exclusive rights to to develop and commercialize assays based on miRNAs validated by Moffitt researcher Johnathan Lancaster. The company said it would initially focus on a test that can predict an ovarian cancer patient's response to treatment, and expects to have a product ready for market in 18 to 24 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.